Aeterna Zentaris Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Aeterna Zentaris Inc. – Product Pipeline Review – 2016’, provides an overview of the Aeterna Zentaris Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Aeterna Zentaris Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Aeterna Zentaris Inc.

The report provides overview of Aeterna Zentaris Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Aeterna Zentaris Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Aeterna Zentaris Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Aeterna Zentaris Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Aeterna Zentaris Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aeterna Zentaris Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Aeterna Zentaris Inc. Snapshot 6

Aeterna Zentaris Inc. Overview 6

Key Information 6

Key Facts 6

Aeterna Zentaris Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Aeterna Zentaris Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Aeterna Zentaris Inc. - Pipeline Products Glance 14

Aeterna Zentaris Inc. - Late Stage Pipeline Products 14

Phase III Products/Combination Treatment Modalities 14

Aeterna Zentaris Inc. - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Aeterna Zentaris Inc. - Early Stage Pipeline Products 16

IND/CTA Filed Products/Combination Treatment Modalities 16

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Aeterna Zentaris Inc. - Drug Profiles 19

zoptarelin doxorubicin 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

macimorelin acetate 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

ozarelix 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

AEZS-120 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

AEZS-124 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

AEZS-125 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

AEZS-126 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

AEZS-134 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

AEZS-138 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

AEZS-140 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Small Molecules for Undisclosed Indication 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Aeterna Zentaris Inc. - Pipeline Analysis 34

Aeterna Zentaris Inc. - Pipeline Products by Target 34

Aeterna Zentaris Inc. - Pipeline Products by Route of Administration 35

Aeterna Zentaris Inc. - Pipeline Products by Molecule Type 36

Aeterna Zentaris Inc. - Pipeline Products by Mechanism of Action 37

Aeterna Zentaris Inc. - Recent Pipeline Updates 38

Aeterna Zentaris Inc. - Dormant Projects 48

Aeterna Zentaris Inc. - Discontinued Pipeline Products 49

Discontinued Pipeline Product Profiles 49

AEZS-115 49

AEZS-123 49

AEZS-131 49

AEZS-132 50

AN-215 50

AN-238 50

perifosine 50

teverelix 50

Aeterna Zentaris Inc. - Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Aeterna Zentaris Inc., Key Information 6

Aeterna Zentaris Inc., Key Facts 6

Aeterna Zentaris Inc. – Pipeline by Indication, 2016 9

Aeterna Zentaris Inc. – Pipeline by Stage of Development, 2016 10

Aeterna Zentaris Inc. – Monotherapy Products in Pipeline, 2016 11

Aeterna Zentaris Inc. – Out-Licensed Products in Pipeline, 2016 12

Aeterna Zentaris Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 13

Aeterna Zentaris Inc. – Phase III, 2016 14

Aeterna Zentaris Inc. – Phase II, 2016 15

Aeterna Zentaris Inc. – IND/CTA Filed, 2016 16

Aeterna Zentaris Inc. – Preclinical, 2016 17

Aeterna Zentaris Inc. – Discovery, 2016 18

Aeterna Zentaris Inc. – Pipeline by Target, 2016 34

Aeterna Zentaris Inc. – Pipeline by Route of Administration, 2016 35

Aeterna Zentaris Inc. – Pipeline by Molecule Type, 2016 36

Aeterna Zentaris Inc. – Pipeline Products by Mechanism of Action, 2016 37

Aeterna Zentaris Inc. – Recent Pipeline Updates, 2016 38

Aeterna Zentaris Inc. – Dormant Developmental Projects,2016 48

Aeterna Zentaris Inc. – Discontinued Pipeline Products, 2016 49

Aeterna Zentaris Inc., Subsidiaries 51

List of Figures

List of Figures

Aeterna Zentaris Inc. – Pipeline by Top 10 Indication, 2016 8

Aeterna Zentaris Inc. – Pipeline by Stage of Development, 2016 10

Aeterna Zentaris Inc. – Monotherapy Products in Pipeline, 2016 11

Aeterna Zentaris Inc. – Out-Licensed Products in Pipeline, 2016 12

Aeterna Zentaris Inc. – Pipeline by Top 10 Target, 2016 34

Aeterna Zentaris Inc. – Pipeline by Route of Administration, 2016 35

Aeterna Zentaris Inc. – Pipeline by Molecule Type, 2016 36

Aeterna Zentaris Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 37

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports